Compare CVM & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVM | ONMD |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 25.0M |
| IPO Year | 1996 | 2021 |
| Metric | CVM | ONMD |
|---|---|---|
| Price | $1.79 | $4.51 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 265.5K | 53.9K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | N/A | ★ N/A |
| Revenue | $264,033.00 | ★ $1,359,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 65.45 | ★ 111.35 |
| 52 Week Low | $0.89 | $0.63 |
| 52 Week High | $9.35 | $140.05 |
| Indicator | CVM | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 28.53 |
| Support Level | $1.01 | $0.63 |
| Resistance Level | $2.83 | $39.25 |
| Average True Range (ATR) | 0.27 | 0.43 |
| MACD | -0.06 | 0.63 |
| Stochastic Oscillator | 12.82 | 34.92 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.